Tirzepatide vs Semaglutide: Which Works Better for UK Weight Loss?

META: Compare tirzepatide (Mounjaro) and semaglutide (Wegovy) for weight loss. Latest evidence on cardiometabolic outcomes for UK patients choosing between GLP-1s.

The scale tips differently depending on who you ask. Ask a cardiologist about GLP-1 treatment and you’ll hear one answer. Ask an endocrinologist and you might hear another. But when you’re choosing between tirzepatide and semaglutide — the two drugs now reshaping weight loss medicine in the UK — the answer matters most to you.

A recent meta-analysis published in 2026 pulled together data from multiple randomised trials comparing these drugs head-to-head. What emerged was neither a clear winner nor a dead heat, but rather two different tools solving the same problem in subtly different ways. One packs more punch on the scales. The other has a longer track record. One excels at controlling blood sugar. The other suits your heart. Understanding which one fits your body — and your risk profile — requires looking past the headlines to the actual numbers.

The Weight Loss Gap: Why Numbers Alone Tell Half the Story

Let’s start with what everyone wants to know: which drug makes you lose more weight?

Tirzepatide wins. Not by a whisker. The data shows tirzepatide produces approximately 22% body weight loss over 68 weeks when taken at maximum tolerated doses, whilst semaglutide achieves around 16% under the same conditions. That’s roughly 6 percentage points in tirzepatide’s favour — enough to mean an extra stone and a half for someone starting at 100 kilograms.

Here’s the wrinkle: that difference shrinks when you look at real-world prescribing. Many patients can’t tolerate tirzepatide’s maximum dose due to side effects, particularly nausea and vomiting in the first weeks. Semaglutide, being slightly gentler on the stomach, often gets tolerated at effective doses more consistently. So the gap on paper (6 percentage points) doesn’t always translate to the gap at home (where people actually live with their treatment).

Both drugs work by mimicking GLP-1, a hormone that tells your brain you’re full. Tirzepatide adds a second mechanism — it also mimics GIP, another hormone that affects how your body handles fat and glucose. That dual action explains the extra weight loss. But here’s what matters clinically: beyond a certain point, extra weight loss plateaus. Both drugs get most people to a medically significant weight reduction — typically 10% or more — which is where cardiovascular benefits actually kick in.

Cardiometabolic Outcomes: Where the Real Differences Emerge

Blood Sugar Control

If you have type 2 diabetes or prediabetes, this section is why you’re reading this article.

Tirzepatide reduces HbA1c (the three-month blood sugar average) by roughly 2.5 percentage points in people with diabetes. Semaglutide manages about 1.8 percentage points. That difference — whilst it sounds academic — translates to substantially better glucose control for tirzepatide users, particularly those with poorly controlled diabetes at baseline.

The GIP component matters here. GIP promotes insulin secretion and reduces glucagon (the hormone that raises blood sugar). Semaglutide, lacking that GIP action, relies entirely on GLP-1’s effects: slowing stomach emptying, increasing insulin release, and blunting appetite. Both work, but tirzepatide works through more levers.

Blood Pressure and Lipids

Both drugs lower blood pressure — we’re talking reductions of 6–10 mmHg systolic, which is clinically meaningful. Neither has a clear advantage here; they’re roughly matched.

Triglycerides tell a different story. Tirzepatide drops triglyceride levels by 30–35% whilst semaglutide manages 20–25%. If you have metabolic syndrome — that constellation of high triglycerides, low HDL, high blood pressure, and central obesity — tirzepatide’s stronger triglyceride effect could matter for your heart health long-term. Cardiovascular disease risk doesn’t hinge on triglycerides alone, but they’re a piece of the puzzle.

The Heart Protection Question

Here’s where semaglutide has the edge, at least in one specific domain: proven heart attack and stroke prevention in people with established cardiovascular disease.

The SUSTAIN-6 trial, published in the New England Journal of Medicine, showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 26% in people with type 2 diabetes and existing heart disease. That’s a landmark finding. Tirzepatide hasn’t yet completed equivalent cardiovascular outcome trials in that population — the trials are ongoing, and we won’t have results for another year or two.

This matters if you’ve already had a heart attack or stroke, or if you have severe coronary disease. Semaglutide has proven protection in that specific group. Tirzepatide almost certainly offers it too (the weight loss and metabolic improvements suggest it should), but that proof hasn’t arrived yet in the form of published randomised trial data.

Safety, Tolerability, and Real-World Use

Both drugs cause nausea. Tirzepatide tends to cause more of it, particularly in the first month. Some patients describe it as manageable; others stop treatment because of it. Semaglutide is gentler on most stomachs, though nausea still affects a significant minority.

Dehydration and kidney function concern clinicians more than patients realise. When you lose weight rapidly and cut food intake, your kidneys respond. Both drugs carry warnings about using them cautiously in people with kidney disease. Neither is contraindicated in mild-to-moderate impairment, but dose adjustments may be needed. Regular blood tests catch this.

Pancreatitis — inflammation of the pancreas — has been reported with both drugs, though it’s rare (fewer than 1 in 1,000 users). The link is debated; some researchers believe the weight loss itself reduces pancreatitis risk by lowering pancreatic fat. Either way, it’s not a reason to avoid either drug if you don’t have prior pancreatitis, but it’s worth knowing if you do.

Semaglutide has been in clinical use longer — approved by the MHRA since 2018 for diabetes, 2021 for weight loss. That means we have longer real-world safety follow-up. Tirzepatide only gained MHRA approval for weight loss in 2023. Five years of additional observational data does matter when you’re choosing a lifelong treatment, even if it shouldn’t on paper.

Cost, Access, and Prescription in the UK

The NHS doesn’t routinely fund either drug for weight loss alone. Both are available privately through licenced clinics, and both cost roughly £150–250 per month depending on dose.

Tirzepatide often requires slightly higher cumulative doses to reach maximum effect, which can push costs higher. Semaglutide reaches clinical benefit at lower maintenance doses for many patients, potentially working out cheaper long-term.

If you have type 2 diabetes (not just prediabetes), your GP may prescribe semaglutide on the NHS as a diabetes treatment, with weight loss as a secondary benefit. Tirzepatide is less commonly prescribed by GPs because it’s newer and less familiar, though that’s changing. For straightforward weight loss in people without diabetes, private prescription remains the typical route for both.

So Which One Should You Choose?

Tirzepatide if: you have type 2 diabetes or metabolic syndrome (especially high triglycerides), you need maximum weight loss, and you can tolerate nausea in the first month. The stronger blood sugar control and triglyceride reduction make it the logical choice for metabolic disease.

Semaglutide if: you have a history of heart attack or stroke (where the cardiovascular outcome data is strongest), you’re sensitive to nausea, or you prefer a treatment with a longer safety track record. It’s equally effective for weight loss in real-world settings and slightly easier to tolerate for many people.

Neither choice is wrong. Both are GLP-1s, both work through similar mechanisms, and both produce clinically significant weight loss alongside metabolic improvements. The differences we’ve discussed — 6 percentage points on weight, 0.7 percentage points on HbA1c, 10 percentage points on triglycerides — matter for specific people in specific situations. They don’t matter uniformly for everyone.

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide if I’m not losing enough weight?

Yes, many clinicians do this. You’ll typically stop semaglutide, wait a week, then start tirzepatide at a lower dose to avoid side effects. The transition usually takes 4–8 weeks. Whether it’s worth the disruption depends on how close you are to your goal — if you’re already 15% down, the extra 6% from switching might not justify the restart nausea.

Which drug is better for someone with high blood pressure?

Neither has a clear advantage for blood pressure reduction alone — both lower systolic and diastolic by roughly similar amounts (6–10 mmHg). If you also have high triglycerides or diabetes, tirzepatide’s broader metabolic effects make it the better choice. If you have heart disease, semaglutide’s proven cardiovascular protection wins out.

Do I need to stay on these drugs forever?

Weight typically returns within 12 months if you stop either drug. Most people remain on them long-term, treating them like blood pressure or cholesterol medication — a chronic disease tool rather than a temporary course. Some patients take breaks or use lower maintenance doses once they’ve reached their target.

What happens if I can’t tolerate the nausea?

Start at the lowest dose and increase slowly (the approved schedule is one injection weekly, increasing to the next dose every four weeks). Eat small, frequent meals and avoid fatty or greasy food. If tirzepatide’s nausea persists beyond week six, switching to semaglutide often resolves it. Genuine intolerance to GLP-1s themselves is rare; it’s usually a dose escalation issue.

Are these drugs safe for someone with a family history of thyroid cancer?

GLP-1s carry a theoretical warning about thyroid cancer based on rodent studies, but human evidence of actual harm is absent. The MHRA advises caution in people with personal or family history of medullary thyroid cancer (a specific rare type). If your family history is just “thyroid cancer” without specifying the type, discuss it with your clinician — most cases are fine to treat. Avoid GLP-1s entirely only if you or a close relative had medullary thyroid cancer specifically.

The choice between tirzepatide and semaglutide ultimately depends on what you’re treating — weight alone, weight plus diabetes, or weight plus heart disease prevention. Both deliver results. Both have minor risks worth knowing about. Both require ongoing medication. The best drug is the one you’ll actually take consistently, tolerate without abandoning, and that targets your specific metabolic problems. Our clinicians assess your full health picture — including blood sugar, cholesterol, heart history, and kidney function — before recommending one over the other. That personalised approach beats generic guidelines every time. If you’d like to explore which fits your situation, we can help you find out.